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Abstract
Aim: To evaluate the efficacy and safety of SK3530, a newly developed type 5 phosphodiesterase inhibitor (PDE5I), in
Korean men with erectile dysfunction (ED).  Methods: A total of 119 patients were randomized at 10 centers in Korea to
receive either SK3530 (50, 100, or 150 mg; n = 89) or placebo (n = 30) taken l h before anticipated sexual activity for an
8-week period.  The patients were evaluated at baseline and 4 and 8 weeks after beginning therapy.  Efficacy was
assessed using the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP), and the Global
Assessment Question (GAQ).  Safety was analyzed by adverse events, laboratory values and vital signs.  Results: At the
end of the study, all the primary and secondary efficacy end-points were statistically significantly improved by SK3530
compared with placebo (P < 0.05).  Of the 89 patients in the treatment arm, 36 (42.3 %) achieved normal erectile
function after treatment, including six patients with severe ED.  Treatment-related adverse events occurred in 32 patients.
The most common adverse events were flushing, headache, dizziness and eye redness (10.9%, 7.6%, 2.5% and 2.5%,
respectively), and most were mild.  Only two patients discontinued treatment during the study period because of adverse
events.  Conclusion: The results of our phase II study have confirmed the efficacy and safety of SK3530 in a broad
population of men with ED of various etiologies and severity.  The optimal doses in terms of efficacy and safety were
determined to be 50 mg and 100 mg, respectively.  (Asian J Androl 2008 Sep; 10: 791–798)
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1    Introduction
Erectile dysfunction (ED) is highly prevalent in Asian
men [1], and can be distressing because of its effect on
self-esteem, quality of life and interpersonal relationships
[2, 3].  Three major type 5 phosphodiesterase (PDE5)
inhibitors (PDE5Is), sildenafil, tadalafil and vardenafil,
have been shown to be effective in treating ED of vary-
ing functional severity and etiology [4–6].  However, a
substantial number of patients are believed to discon-
tinue treatment in the long term [7–9].  The main reason
for the poor compliance rate proved to be the lowered
efficacy that did not meet patients’ expectations [9].  If
one PDE5I does not satisfy a patient’s expectations, the
availability of another PDE5I might provide a better op-




is a novel pyrrolopyrimidinone compound and a potent
and reversible PDE5I [10–11].  Several key clinical phar-
macokinetic and pharmacodynamic data have revealed
that SK3530 has acceptable pharmacologic properties
(Table 1).  In particular, the selectivity ratios, which ex-
press the x-fold differences in inhibitory activity for a
specific PDE compared with PDE5, has revealed com-
parable selectivity of SK3530 with other conventional
PDE5Is.  A previous preclinical study revealed that the
IC50 of PDE5 for SK3530 is 10-fold lower than that of
sildenafil, a protodrug of PDE5I [10].  In contrast, its
inhibitory effects on other phosphodiesterases, such as
PDE1 and PDE11, are much lower than those of sildenafil
(Table 1) [12].  Moreover, a phase I study revealed that
SK3530 is well tolerated at daily doses of up to 200 mg
in healthy volunteers (COVANCE, unpublished data,
2003).  Thus, the aim of the present trial was to evaluate
the effect of on-demand SK3530 therapy at fixed doses
(50, 100 and 150 mg) in Korean men with a broad range
of ED severity, and to determine the optimal dose with
respect to effectiveness and patient tolerance.
2     Materials and methods
2.1  Study design
This phase II, multicenter, randomized, double-blind,
placebo-controlled, four-arm, parallel group, fixed dose
comparison of 50, 100 and 150 mg SK3530 vs. placebo
consisted of three parts: 1) a 4-week run-in period with-
out any ED treatment; 2) randomization to 8 weeks of
treatment with SK3530 or placebo; and 3) a 1-week fol-
low-up period for continued adverse event monitoring.
The eligible patients were men aged 19–70 years with
ED, defined as an inability to achieve or maintain a penile
erection sufficient for satisfactory sexual intercourse,
evident for a period longer than 6 months.  To be en-
rolled in the treatment phase of the study, the patients
were required to have experienced a 50% or greater failure
rate in maintaining an erection sufficient to complete in-
tercourse on at least four separate attempts during the 4-
week treatment-free baseline period.  The patients were
excluded from eligibility if they were determined by an
investigator to have experienced a serious cardiovascu-
lar condition within the previous 6 months (e.g., myo-
cardial infarction, unstable angina, a significant electro-
cardiograph conduction defect, congestive heart failure
of New York Heart Association class 2 or greater, or a
Table 1. Comparative key clinical pharmacokinetic and pharmacodynamic data of phosphodiesterase (PDE) inhibitors.  AUC, area under
curve; Cmax, maximal drug concentration; IC50, concentration that inhibits 50% of phosphodiesterase; PDE, phosphodiesterase; T1/2, half
life; Tmax, time of maximal concentration.
Parameter SK3530 Sildenafil [12] Vardenafil [12]                  Tadalafil [12]
Tmax (range, h) 1.4 (0.8–2.0) 1 (0.5–2.0) 0.7 (0.25–3.0)                   2 (0.5–6.0)
Cmax (µg/L) (tested dose) 298.9 (100 mg) 560 (100 mg) 20.9 (20 mg)                      378 (20 mg)
AUC (h·µg/L) (dose) 790.7 (100 mg) 1 685 (100 mg) 74.5 (20 mg)                      8 066 (20 mg)
T1/2 (h) 2.5 3–5 4–5                                    17.5
IC50 for PDE5 (nmol/L) 0.3 3.5–8.5 0.1–0.7                              0.94–6.4
IC50 for PDE1 (nmol/L) 16 400 41 136                                    > 1 000
IC50 for PDE3 (nmol/L) 86 500 > 1 000 > 1 000                              > 1 000
IC50 for PDE6 (nmol/L) 10.2 7.4 15                                      780
IC50 for PDE11 (nmol/L) 3750 203 346                                    7.1
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stroke), or a systolic blood pressure > 170 mmHg or
< 90 mmHg, or a diastolic blood pressure > 100 mmHg
or < 50 mmHg, or if they were being treated with nitrates.
Other exclusion criteria included anatomic abnormalities
of the penis that could impair sexual intercourse,
hypoactive sexual desire,  a  history of radical
prostatectomy, ED after spinal cord injury, retinitis
pigmentosa, chronic liver disease, major hematologic
disorder, poorly controlled diabetes (hemoglobin A1c
greater than 12 %), or a history of peptic ulcer disease
within 1 year.  Any patients who had experienced previ-
ous ineffective treatment with sildenafil, vardenafil, or tadalafil
were also excluded.  During the treatment period, the use of
anti-androgens, anticoagulants, androgens, drugs affect-
ing cytochrome P450 3A4 (CYP3A4) metabolism, or
trazodone hydrochloride were not allowed.  The study
was conducted at 10 tertiary-care, academically affiliated
investigative sites in Korea.  The first patient was enrolled
in October 2004, and the study was completed in June
2005.  The ethics committees of the participating institu-
tions approved the final protocol, amendments, and the
informed consent document.
2.2 Treatment
Medical history, a physical examination, laboratory
safety tests and an electrocardiogram were carried out
during each screening visit.  Patients who met all enrol-
ment criteria were randomly allocated to 8 weeks of on-
demand treatment.  The patients were instructed to take
the study medication approximately 1 h before intended
sexual intercourse.  It was recommended that the drug
should be taken at least 1 h after a meal.  Medication use
was monitored using patient medication/outcome diaries,
and the study personnel counted the number of used pills
during the assessment visits.
2.3  Measures
Erectile function was measured using the Interna-
tional Index of Erectile Function (IIEF) and the Sexual
Encounter Profile (SEP) patient diary.  Patients com-
pleted the IIEF at the end of the run-in period and at the
end of each 4-week treatment period.  The erectile func-
tion (EF) domain scores at the start of the run-in period
were used to determine the baseline ED severity.  Pa-
tients recorded every sexual attempt in an SEP diary.
Global assessment question (GAQ) scores were also
assessed.
The primary efficacy measures were changed in the
response to IIEF question 3 (Q3: Freguency of
penetration) and question 4 (Q4: Freguency of maintained
erection).  The secondary efficacy end-points were
changed between baseline and week 8 in the IIEF EF
domain scores, the percentage of “yes” responses to SEP
Q2 (penetration), SEP Q3 (successful intercourse) and
the GAQ score.
At each patient visit, a safety assessment was car-
ried out that included the recording of adverse events
and vital signs.  A physical examination with routine labo-
ratory testing was carried out at randomization and at ev-
ery treatment visit.
2.4  Statistical analysis
An intent-to-treat analysis of each of the efficacy
variables included all patients with a baseline and at least
one post-baseline observation.  The last-observation-car-
ried-forward imputation method was used for missing
data.  Only variable age was significantly different be-
tween the placebo group and each of the SK3530 groups.
Therefore, the ANCOVA method, using age and baseline
as covariates, was used to evaluate the primary efficacy
end-points and all secondary end-points, except for the
GAQ.
The GAQ was assessed using the χ2-test.  The test-
ing of the hypotheses included comparisons of each
SK3530 dosage group with placebo; therefore, Bonfer-
roni’s adjustment was used.  Statistical significance was
accepted at the P < 0.05 level.
The number of patients needed for this study was
determined by both primary efficacy variables, IIEF Q3
and Q4.  The sample size calculations assumed a stan-
dard deviation of 1.06 for Q3 and 1.22 for Q4, as indi-
cated in a previous Korean study on sildenafil [13].  Treat-
ment differences considered to be clinically significant
were awarded 1.6 and 1.7 points for each question.
With approximately 23 valid patients per group, this
study had the power of approximately 90% for the two
questions.  Allowance for a 20% withdrawal rate required
a total of 116 randomized patients for efficacy analysis,
with 29 per group.  The safety analysis included all pa-
tients who had taken the drug at least once.  Changes
from baseline in the continuous safety variables (laboratory
analysis and vital signs) were evaluated by ANOVA.  Be-
tween groups, comparisons of treatment-emergent ad-
verse event frequencies were conducted using the χ2-
test.  Baseline demographics in the SK3530 and placebo
groups were compared using ANOVA for continuous
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variables and the χ2-test for categorical variables.
3     Results
3.1 Patient population and demographics
A total of 119 men at 10 study centers completed the
baseline evaluations and were randomized for treatment
with placebo (n = 30) or SK3530 at 50 mg (n = 30),
100 mg (n = 30), or 150 mg (n = 29).  During the
8 weeks of therapy, five men (4.2%) withdrew from the
study: three men (one each in the placebo, 100 mg and
150 mg groups) committed a protocol violation and were
excluded; and two men (one each in the 50 mg and
100 mg groups) withdrew because of adverse events.  A
total of 119 and 116 men were valid for the safety and
intent-to-treat analyses, respectively (Figure 1).
At baseline, no clinically or statistically meaningful
differences were found among the treatment groups with
respect to any demographic or clinical variables except
age (P = 0.02).  The mean age of the placebo group was
lower than that of the SK3530 groups.  However, there
were no significant differences in age distribution as a
categorical variable (P = 0.46; Table 2).
Overall, patients were diagnosed as having ED for a
mean of 50.9 months before screening.  Of the 119 study
subjects, 46 (38.7%) had had previous experience with
a PDE5I.  However, no significant difference was found
among the study groups in this respect.  In addition, the
distribution of comorbid diseases was not statistically
different between treatment groups (P = 0.46 by Fisher’s
exact test; Table 2).
3.2  Efficacy and treatment satisfaction
At baseline, the mean EF domain scores ranged from
Figure 1. Progress of patients through study to evaluate the efficacy and safety of SK3530, a newly developed type 5 phosphodiesterase
inhibitor (PDE5I), in Korean men with erectile dysfunction (ED).  ITT, intent-to-treat.
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13 to 15 and there were no significant differences in
severity of ED among the groups.  After 8 weeks of
treatment, the primary efficacy measures, IIEF Q3 and
Q4, indicated a significant positive effect for all SK3530
doses compared with placebo (P < 0.01; Figure 2).  For
those taking 100 mg SK3530, the mean Q3 score in-
creased from 2.6 at baseline to 4.4 at week 8, and the
mean Q4 score increased from 1.7 at baseline to 3.9 at
the same time point.
Similar results were obtained for the secondary effi-
cacy measures (Figure 3).  The change from baseline to
end-point on the IIEF EF domain (maximal score 30)
was 8.4, 10.7 and 8.2 for the 50, 100 and 150 mg groups,
respectively, compared with 2.3 for placebo (P < 0.01).
In addition, SK3530 significantly improved the percent-
age of successful penetrations (SEP Q2) and successful
intercourse completions (SEP Q3) compared with
placebo.  In the SK3530 treatment groups, the mean SEP
Q2 score increase ranged from 28.4% to 37.9% com-
pared with 8.3% in the placebo group (P < 0.01).  The
range of the SEP Q3 increases was 44.9% to 63.2%,
significantly greater than that of placebo (18.6%, P < 0.05).
The superior efficacies of these doses were main-
tained during treatment.  The beneficial effect of SK3530
was apparent by GAQ analysis (Figure 3).  Of the intent-
to-treat group, the proportion of affirmative responders
to the GAQ was significantly greater for the three SK3530
groups than for the placebo group (P < 0.01).  At the
end of the study, 75.9% of the 50 mg group, 86.2% of
the 100 mg group, and 82.1% of the 150 mg group de-
scribed a positive response to the GAQ vs. 34.5% of the
placebo group.
SK3530 was able to induce normal EF (EF domain
score greater than 25), irrespective of baseline ED severity.
After 8 weeks of treatment, 36 men (42.3%) in the treat-
ment group (7 [24.1%] in the 50 mg group, 15 [51.7%]
in the 100 mg group, and 14 [48.3%] in the 150 mg
group) achieved normal EF compared with 5 men (17.
2%) in the placebo group.  For those who regained erec-
tile function, 14 (50.0%), 16 (40%), and 6 (28.6%) had
mild, moderate, and severe ED at baseline, respectively.
3.3  Safety
In general, SK3530 was well tolerated at all given
Table 2. Demographics and clinical characteristics of the study group of Korean men with erectile dysfunction (ED) who participated in a
phase II trial of SK3530, a newly developed type 5 phosphodiesterase inhibitor (PDE5I).  †Data in parentheses indicate percentage. IIEF-
EFD, erectile function domain in International Index of Erectile Function.
Placebo SK3530
( n = 30) 50 mg 100 mg 150 mg
(n = 30) (n = 30) (n = 29)
Mean age at enrolment (years) 49.7 54.2 55.4 53.6
Median interval since first noticed ED (months) 36.5 37.5 36.0 60.0
Severity of ED (n) stratified by IIEF-EFD†
Severe (≤ 10) 4 (13.3) 9 (30.0) 6 (20.0) 6 (20.7)
Moderate (11–16) 15 (50.0) 15 (50.0) 16 (53.3) 9(31.0)
Mild (17–25) 11 (36.7) 6 (20.0) 8 (26.7) 14 (48.3)
Etiology (n)†
Organic 18 (60.0) 18 (60.0) 14 (46.7) 15 (51.7)
Psychogenic 2 (6.7) 3 (10.0) 4 (13.3) 2 (6.9)
Mixed 10 (33.3) 9 (30.0) 12 (40.0) 12 (41.4)
Current alcohol consumption (% Yes) 83 60 70 76
Smoking history (% Yes) 60 67 50 59
Previous experience with PDE5I (n)† 12 (40.0) 13 (43.3) 9 (30.3) 12 (30.0)
Medical history (n)†
Hypertension 8 (26.7) 11 (36.7) 7 (23.3) 9 (31.0)
Hyperlipidemia 1 (3.3) 2 (6.6) 0 (0.0) 1 (3.3)
Type 2 diabetes 7 (23.3) 4 (13.3) 6 (20.0) 6 (20.7)
Prostatic hyperplasia 3 (10.0) 4 (13.3) 3 (10.0) 5 (17.2)
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Figure 3. Comparison of secondary efficacy variables (Sexual Encounter Profile [SEP] questions 2 [penetration] and 3 [successful intercourse],
erectile function [EF] domain of the International Index of Erectile Function [IIEF], and Global Assessment Question [GAQ]) between
placebo and various treatment groups. Three SK3530 groups showed significantly superior improvement in various aspects of EF to
placebo following 8 weeks of treatment. *P < 0.05 vs. placebo.
Figure 2. Comparison of primary efficacy variables (questions 3 [Q3] and 4 [Q4] of the International Index of Erectile Function [IIEF]).
Compared to placebo, the treatment with SK3530 significantly improved all tested variables regardless of doses. Q3 of IIEF is, “When you
attempted sexual intercourse, how often were you able to penetrate your partner?”.  Q4 is, “During sexual intercourse, how often were you
able to maintain your erection after you had penetrated your partner?”. *P < 0.05 vs. placebo.
Asian J Androl 2008; 10 (5): 791–798
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doses.  Although the 150 mg group experienced signifi-
cantly more treatment-emergent adverse events, all ad-
verse events were mild or moderate in intensity (Table
3).  The most common treatment-emergent adverse events
were 13 cases (10.9%) of facial flushing, 9 (7.6%) of
headache, and 3 (2.5%) of dizziness and eye redness.
Two men withdrew from the study because of ad-
verse events (one in the 50 mg group and one in the
100 mg group).  No clinically significant changes in the
laboratory parameters or vital signs occurred.
4     Discussion
The results of this study indicated that SK3530 dos-
ages of 50, 100 and 150 mg are significantly superior to
placebo for the treatment of ED, as determined by the
primary study end-points of IIEF Q3 and Q4.  In both
questions, the mean increases from baseline ranged from
1.6 to 2.2, significantly greater than that for placebo
(range, 0.2–0.7).  Also, all doses of SK3530 were sig-
nificantly superior to placebo for the various secondary
study end-points (EF domain score, diary-recorded suc-
cess rates for penetration and maintenance of erection
during intercourse, and the GAQ).
The results are quite comparable to those of a previ-
ous phase III trial of sildenafil in a similar population.
Choi et al.  [13] reported results after 8 weeks of sildenafil
treatment with a flexible dosing regimen.  The changes
in IIEF Q3 and Q4 from baseline were 1.6 and 1.9,
respectively.  Treatment-related adverse events were ob-
served in 56% of the sildenafil arm.  Our study adopted
a fixed dose regimen and included 39% of patients who
had experienced other PDE5Is.  Comparison with the
results from the previous Korean study supports the be-
lief that SK3530 might be at least as efficacious as
sildenafil.
One of the interesting findings was that SK3530 en-
abled approximately 42% of patients to achieve normal
EF; 50% of patients with mild ED and up to 29% of
patients with severe ED who received SK3530 achieved
normal EF (as determined from EF domain scores greater
than 25).  As was stressed by Mulhall [14], the percen-
tage of those regaining normal EF can be clinically mean-
ingful when comparing the efficacy of the drug evaluated.
Despite the difference in dosing design and treatment
duration, our results were comparable with previous tri-
als of vardenafil and tadalafil [15, 16].  SK3530 was well
tolerated.  The adverse events often noted with its use,
flushing, headache, dizziness, and eye redness, were ex-
pected from the pharmacology of PDE5Is [17] and the
results from clinical trials of other PDE5Is [15, 16].  All
of the adverse events recorded for patients in the present
trial were mild or moderate in severity and typically re-
solved with continued use of the drug.  Only two pa-
tients discontinued during the study period because of
adverse events.  Given the nature of fixed dosing, which
disallowed dose reductions resulting from poor
tolerability, this finding might be additional evidence of
the safety of SK3530.
Concerns might be raised regarding the benefit of a
new PDE5I with similar efficacy and safety to pre-exist-
ing ones.  However, a number of studies have indicated
that preference for a medication depends on factors other
than efficacy, safety and tolerability [12, 18].  Besides
efficacy and safety, preference could be determined by
factors such as mode of action, duration, food interaction,
and cost.  Therefore, we believe that the addition of a
new PDE5I that has a unique pharmacologic profile would
benefit someone that was not satisfied with their current
medication.
Concurrent medical diseases such as hypertension
and diabetes could affect the response to PDE5Is.
Therefore, the number of patients with various
comorbidities should be equally distributed between the
tested groups.  This is not always the case, especially in
a trial with a small number of patients.  Fortunately, each
group in this study was balanced in terms of the number
of patients with comorbidities.  If there is any concern
about unequal distribution between groups regarding the
number or severity of comorbidities, the use of validated
Table 3. Summary of treatment-related adverse events in study group
of Korean men with erectile dysfunction who participated in a phase
II trial of SK3530, a newly developed type 5 phosphodiesterase
inhibitor (PDE5I).  *P < 0.05 vs. placebo.
Drug-related SK3530
adverse event Placebo 50 mg 100 mg 150 mg
Flushing      0      5      2      6
Headache      0      1      2      6
Eye redness      0      1      1      1
Dizziness      1      0      1      1
Nasal congestion      0      0      1      1
Epigastric soreness      0      0      1      1
Other      0      2      3      4
Total      1      9*    11*    20*
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comorbidity indices, such as the Charlson comorbidity
index [19], might be of help .
Another important aim of this phase II study was to
determine the optimal dosage of SK3530.  The efficacy
and safety results showed that 100 mg and 50 mg were
associated with the greatest efficacy and lowest adverse
events, respectively.  Thus, it would be rational to exam-
ine the efficacy and safety of 50 mg and 100 mg dosing
in a future phase III study.
This multicenter, randomized, double-blind, placebo-
controlled phase II trial showed that SK3530 safely im-
proved all efficacy parameters of erection in a broad popu-
lation of men with ED of varying etiologies and severity.
The most efficacious and safest doses were determined
to be 100 mg and 50 mg, respectively.
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